We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Repligen (RGEN) Stock Down Despite Q4 Earnings & Sales Beat
Read MoreHide Full Article
Repligen Corporation (RGEN - Free Report) reported fourth-quarter 2019 earnings per share of 20 cents, beating the Zacks Consensus Estimate of 18 cents. The figure also surpassed the year-ago earnings of 19 cents.
Moreover, total revenues of $69.5 million exceeded the Zacks Consensus Estimate of $68 million. Additionally, the top line surged 34% year over year (35% at constant currency) on strong performances by the filtration and chromatography product franchises.
We remind investors that last May, Repligen acquired the privately held bioprocess analytics company C Technologies for a $240-million cash-and-stock deal. Excluding the impact of currency and acquisitions/divestures, Repligen’s revenues grew 21% organically year over year in the fourth quarter.
On the fourth-quarter conference call, management stated that within the seven months of its ownership, revenues from C Technologies products totaled $16.4 million, in line with the company’s expectation.
Despite earnings and sales topping expectations, shares of Repligen were down 7.4% on Thursday. However, the stock has soared 71.8% in the past year against the industry’s decline of 1.8%.
Quarter in Detail
In the reported quarter, adjusted research and development expenses were $4.9 million, up 63.3% from the year-ago figure.
Adjusted selling, general and administrative expenses were $22.2 million, surging 54.2% year over year.
Adjusted gross margin was 57.2%, reflecting a 240-bps improvement compared from the 2018-level. Adjusted operating income was $12.7 million, reflecting an increase of 15% year over year.
As of Dec 31, 2019, Repligen had cash and cash equivalents worth $528.4 million compared with $513.5 million on Sep 30, 2019.
Full-Year Results
For 2019, Repligen generated revenues of $ 270.2 million, up 39% year over year (41% at constant currency) with organic growth of 33%.
Adjusted earnings per share of $1.07 were higher than the year-ago earnings of $0.66.
2020 Guidance
Repligen expects total revenues in the range of $309-$319 million, implying an organic growth of 10-14%.
Adjusted net income is projected in the range of $57-$60 million while adjusted operating income is anticipated in the band of $70-$74 million.
Adjusted EPS is anticipated within $1.07-$1.12 for 2020.
Repligen Corporation Price, Consensus and EPS Surprise
Repligen currently sports a Zacks Rank #1 (Strong Buy). Other top-ranked stocks from the healthcare sector include Aduro Biotech, Inc. , Vericel Corporation (VCEL - Free Report) and Oncolytics Biotech Inc. (ONCY - Free Report) , all sporting the same top Zacks Rank as Repligen. You can see the complete list of today’s Zacks #1 Rank stocks here.
Aduro’s loss per share estimates have been narrowed 10.5% for 2020 over the past 60 days.
Vericel’s earnings estimates have been revised 112.5% upward for 2020 over the past 60 days.
Oncolytics’ loss per share estimates have been narrowed 11.9% for 2020 over the past 60 days. The stock has gained 7.8% in the past year.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Repligen (RGEN) Stock Down Despite Q4 Earnings & Sales Beat
Repligen Corporation (RGEN - Free Report) reported fourth-quarter 2019 earnings per share of 20 cents, beating the Zacks Consensus Estimate of 18 cents. The figure also surpassed the year-ago earnings of 19 cents.
Moreover, total revenues of $69.5 million exceeded the Zacks Consensus Estimate of $68 million. Additionally, the top line surged 34% year over year (35% at constant currency) on strong performances by the filtration and chromatography product franchises.
We remind investors that last May, Repligen acquired the privately held bioprocess analytics company C Technologies for a $240-million cash-and-stock deal. Excluding the impact of currency and acquisitions/divestures, Repligen’s revenues grew 21% organically year over year in the fourth quarter.
On the fourth-quarter conference call, management stated that within the seven months of its ownership, revenues from C Technologies products totaled $16.4 million, in line with the company’s expectation.
Despite earnings and sales topping expectations, shares of Repligen were down 7.4% on Thursday. However, the stock has soared 71.8% in the past year against the industry’s decline of 1.8%.
Quarter in Detail
In the reported quarter, adjusted research and development expenses were $4.9 million, up 63.3% from the year-ago figure.
Adjusted selling, general and administrative expenses were $22.2 million, surging 54.2% year over year.
Adjusted gross margin was 57.2%, reflecting a 240-bps improvement compared from the 2018-level. Adjusted operating income was $12.7 million, reflecting an increase of 15% year over year.
As of Dec 31, 2019, Repligen had cash and cash equivalents worth $528.4 million compared with $513.5 million on Sep 30, 2019.
Full-Year Results
For 2019, Repligen generated revenues of $ 270.2 million, up 39% year over year (41% at constant currency) with organic growth of 33%.
Adjusted earnings per share of $1.07 were higher than the year-ago earnings of $0.66.
2020 Guidance
Repligen expects total revenues in the range of $309-$319 million, implying an organic growth of 10-14%.
Adjusted net income is projected in the range of $57-$60 million while adjusted operating income is anticipated in the band of $70-$74 million.
Adjusted EPS is anticipated within $1.07-$1.12 for 2020.
Repligen Corporation Price, Consensus and EPS Surprise
Repligen Corporation price-consensus-eps-surprise-chart | Repligen Corporation Quote
Zacks Rank & Other Stocks to Consider
Repligen currently sports a Zacks Rank #1 (Strong Buy). Other top-ranked stocks from the healthcare sector include Aduro Biotech, Inc. , Vericel Corporation (VCEL - Free Report) and Oncolytics Biotech Inc. (ONCY - Free Report) , all sporting the same top Zacks Rank as Repligen. You can see the complete list of today’s Zacks #1 Rank stocks here.
Aduro’s loss per share estimates have been narrowed 10.5% for 2020 over the past 60 days.
Vericel’s earnings estimates have been revised 112.5% upward for 2020 over the past 60 days.
Oncolytics’ loss per share estimates have been narrowed 11.9% for 2020 over the past 60 days. The stock has gained 7.8% in the past year.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>